New Method May Lessen Breast Cancer Drugs Side-Effects
A drug that has proven effective in the prevention and treatment of breast cancer, but with serious side-effects, may be delivered effectively through the skin using a new topical drug-delivery system. Endoxifen, a commonly used hormone therapy for breast cancer, has also been shown to prevent the disease. However, taken orally, the drug can cause side-effects such as hot flashes and vaginal atrophy, along with increased risk of endometrial cancer and stroke, that leave it wanting as a routine method of chemoprevention.
University of Illinois at Chicago researchers, in collaboration with Northwestern University clinicians, developed a chemical encapsulation for endoxifen and showed in laboratory studies that it may be better than some other techniques used to help the drug cross the skin barrier. The study was published in the journal Advanced Functional Materials in May.
Delivering the drug directly through the breast may reduce the number of mastectomies while lessening the side-effects of oral endoxifen, says Seungpyo Hong, assistant professor of pharmaceutics and bioengineering at UIC and lead author of the paper. Endoxifen, a more active form of its chemical-cousin tamoxifen, must cross multiple layers of skin to reach the site where it can prevent breast cancer, Hong said.
The drug cannot pass through skin layers without the use of penetration enhancers. Hong and his colleagues created dendron-based micelles — essentially, specialized bubbles — to encapsulate endoxifen. They used hairless mouse and human skin samples to test the ability to cross the skin barrier as compared to unencapsulated endoxifen.
"We found that dendron micelles can achieve sufficient loading, enhanced skin permeation, and controlled release of endoxifen, without losing its efficacy, compared to free endoxifen," Hong said.
A water-soluble drug formulation used by the researchers allowed the dendron micelles to deliver endoxifen without the use of chemical penetration enhancers like alcohol or detergent. These small molecules, which make the skin more permeable, may cause irritation. The size of the micelle can determine how easily endoxifen permeates the skin and whether it causes irritation. Compared with ethanol and cationic liposomes, the smaller size of micelles (50 nanometers, versus 100 nm for the liposomes) creates a greater surface-to-volume ratio.
Comparing the speeds at which the different methods carried endoxifen across the skin, the researchers found that cationic liposomes transmitted the drug faster but without stably encapsulating the drug. Although slower, the dendron micelles released the drug in a more controlled manner, a potential advantage, Hong said, for a drug intended for chemoprevention. Given that the target recipients are those who have the potential to develop breast cancer, a slow-release system could reduce dosing frequency, which would significantly increase the patient compliance.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance